Clinical Trial Update: EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Zeprumetostat, an EZH2 inhibitor, is being evaluated in combination therapy for relapsed or refractory mature T-cell and NK-cell lymphomas. The study is in Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mature T-cell Lymphoma
• Natural Killer Cell Lymphoma

Drugs mentioned

• Zeprumetostat (zeprumetostat)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Mature T-cell and NK-cell Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING